Rothschild Asset Management Inc. reduced its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 6.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,512 shares of the medical research company’s stock after selling 301 shares during the period. Rothschild Asset Management Inc.’s holdings in Quest Diagnostics were worth $502,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in DGX. Teachers Advisors LLC boosted its stake in Quest Diagnostics by 6.6% in the fourth quarter. Teachers Advisors LLC now owns 177,243 shares of the medical research company’s stock valued at $16,289,000 after buying an additional 11,003 shares during the last quarter. Creative Planning boosted its stake in Quest Diagnostics by 30.8% in the first quarter. Creative Planning now owns 4,159 shares of the medical research company’s stock valued at $408,000 after buying an additional 980 shares during the last quarter. Gulf International Bank UK Ltd boosted its stake in Quest Diagnostics by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 45,053 shares of the medical research company’s stock valued at $4,423,000 after buying an additional 625 shares during the last quarter. Bank of Montreal Can boosted its stake in Quest Diagnostics by 3.1% in the first quarter. Bank of Montreal Can now owns 292,342 shares of the medical research company’s stock valued at $28,705,000 after buying an additional 8,700 shares during the last quarter. Finally, Atria Investments LLC boosted its stake in Quest Diagnostics by 114.8% in the first quarter. Atria Investments LLC now owns 6,544 shares of the medical research company’s stock valued at $643,000 after buying an additional 3,498 shares during the last quarter. Institutional investors and hedge funds own 90.97% of the company’s stock.

Shares of Quest Diagnostics Incorporated (NYSE DGX) opened at 106.10 on Friday. Quest Diagnostics Incorporated has a 12-month low of $79.12 and a 12-month high of $112.97. The stock’s 50 day moving average is $108.82 and its 200 day moving average is $103.03. The firm has a market cap of $14.47 billion, a price-to-earnings ratio of 21.38 and a beta of 0.69.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.42 by $0.13. Quest Diagnostics had a net margin of 9.28% and a return on equity of 15.66%. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the prior year, the firm posted $1.34 EPS. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. Equities analysts expect that Quest Diagnostics Incorporated will post $5.70 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, July 24th. Stockholders of record on Monday, July 10th were issued a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.70%. The ex-dividend date of this dividend was Thursday, July 6th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.29%.

COPYRIGHT VIOLATION NOTICE: “Rothschild Asset Management Inc. Lowers Position in Quest Diagnostics Incorporated (DGX)” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/13/rothschild-asset-management-inc-lowers-position-in-quest-diagnostics-incorporated-dgx.html.

DGX has been the subject of several research reports. UBS AG upgraded shares of Quest Diagnostics from a “market perform” rating to an “outperform” rating in a research note on Friday, April 21st. Raymond James Financial, Inc. upgraded shares of Quest Diagnostics from a “market perform” rating to an “outperform” rating and set a $116.00 target price for the company in a research note on Friday, April 21st. Deutsche Bank AG reiterated a “buy” rating and issued a $115.00 target price (up previously from $108.00) on shares of Quest Diagnostics in a research note on Sunday, April 23rd. Barclays PLC reiterated an “equal weight” rating and issued a $100.00 target price (up previously from $98.00) on shares of Quest Diagnostics in a research note on Sunday, April 23rd. Finally, Evercore ISI reiterated an “in-line” rating and issued a $104.50 target price (up previously from $102.00) on shares of Quest Diagnostics in a research note on Monday, April 24th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $109.62.

In related news, Director Jeffrey M. Leiden sold 1,304 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $108.73, for a total transaction of $141,783.92. Following the completion of the transaction, the director now directly owns 6,296 shares in the company, valued at approximately $684,564.08. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Catherine T. Doherty sold 59,762 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $107.55, for a total transaction of $6,427,403.10. Following the transaction, the senior vice president now owns 78,582 shares of the company’s stock, valued at $8,451,494.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,362 shares of company stock valued at $6,600,758. 1.50% of the stock is currently owned by insiders.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.